1. Scrip
  2. >>Business

InSite Vision names Louis Drapeau interim CEO

InSite Vision (US) has announced that Louis Drapeau, its vice-president and chief financial officer, has been appointed interim CEO. Dr S Kumar Chandrasekaran will step down as CEO, effective immediately. Mr Drapeau will lead the company's day-to-day operations while retaining his CFO responsibilities; the search for a CEO has begun. In addition, Dr Evan Melrose, managing director of PTV Sciences, has been named chairman of the board.

InSite Vision (US) has announced that Louis Drapeau, its vice-president and chief financial officer, has been appointed interim CEO. Dr S Kumar Chandrasekaran will step down as CEO, effective immediately. Mr Drapeau will lead the company's day-to-day operations while retaining his CFO responsibilities; the search for a CEO has begun. In addition, Dr Evan Melrose, managing director of PTV Sciences, has been named chairman of the board.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By Andy Smith

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By Mandy Jackson

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

More from Scrip

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.